Cardiac Post-Chest Radiotherapy Complications in a 50-Year-Old Patient with Hodgkin Lymphoma

Author:

Klotzka Aneta1,Sobańska Karolina1,Iwańczyk Sylwia1,Grygier Marek1,Woźniak Patrycja1ORCID,Błaszyk Maciej2,Rozwadowska Natalia3ORCID,Lesiak Maciej1

Affiliation:

1. I Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznań, Poland

2. Department of Radiology, Poznan University of Medical Sciences, 61-701 Poznań, Poland

3. Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznań, Poland

Abstract

Lymphomas are a group of malignant tumors that originate in the lymphatic system. It is the most common type of blood cancer. It affects the lymph nodes, spleen, bone marrow, blood, and other organs. They can be aggressive or chronic. Hodgkin lymphoma survival rate is 2 in 100,000 people. Young adults aged 20–30 and people over 50 are most often affected. The prognosis of Hodgkin’s lymphoma is good, with a survival rate of up to 80 percent. Nevertheless, in 20–30 percent of patients who initially respond to treatment, the disease has a tendency to progress. The positive effect of radiotherapy (RT) on patients’ survival rates has been proven in many randomized clinical trials. Although the dose of chest RT has significantly reduced over the years, we still struggle with the long-term complications of post-RT repercussions, mainly because there is no established safe dose of RT affecting the heart. Other complications include earlier onset of coronary artery disease, early and late onset of pericarditis, valve degeneration (predominantly of the left heart), calcification of the aorta and its branches, heart failure, and arrhythmias. One patient can manifest each of the abovementioned complications, as in the present case. That is why choosing the right treatment strategy is crucial.

Publisher

MDPI AG

Subject

General Medicine

Reference14 articles.

1. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS);Lyon;Eur. Heart J.,2022

2. Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification;Bergom;Cardio Oncol.,2021

3. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort;Mulrooney;BMJ,2009

4. Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association;Piotrowski;Pol. Heart J.,2023

5. Thoracic Aortic Calcification: Diagnostic, Prognostic, and Management Considerations;Desai;JACC Cardiovasc. Imaging,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3